To include your compound in the COVID-19 Resource Center, submit it here.

GW433908: Phase III

VRTX and partner GSK said 24-week data from their open-label Phase III NEAT trial showed 73% of 166 patients given GW433908 achieved undetectable

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE